BioSpace News Archive

In an upcoming Healthcare Financial Management Association (HFMA) member webinar, industry experts Jane Hermansen, Manager, Outreach and Network Development at Mayo Clinic Laboratories, and Emily Adams, Director of Outpatient Laboratory at Mount Carmel Health System, will join Mike Fauver, Associate Vice President of Health Systems at XIFIN,

Y2X Life Sciences, a New York-based leader in products that disrupt the transmission of infectious disease, today announced it has entered into an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology that can detect aerosolized SARS-CoV-2.

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care associated with the prevention of sudden cardiac arrest (SCA), a condition in which the heart suddenly and unexpectedly stops beating.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at the Clinical Trials in Rare Diseases Conference on September 14th, 2021.

Dexcom, Inc., a leader in real-time continuous glucose monitoring, is pleased to announce the Dexcom G6 CGM System is now covered by the Non-Insured Health Benefits Program for people living with diabetes who are between 2 and 19 years old and require intensive insulin therapy.

AVITA Medical, Inc. announced today that its management will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. Eastern Daylight Time

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced its financial results for its second quarter and six months ended June 30, 2021.

Exagen Inc. today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30th, 2021.